Neuroprotective Properties of Chlorogenic Acid and 4,5-Caffeoylquinic Acid from Brazilian arnica (Lychnophora ericoides) after Acute Retinal Ischemia

Abstract

Lychnophora is a genus of South American flowering plants in the daisy family, popularly known as “Brazilian arnica”. It is used in traditional medicine as an anti-inflammatory and analgesic agent, whose active components are derived from chlorogenic acid (CGA) and C-flavonoids. Since the drugs currently used are ineffective to treat glaucoma, agents with antioxidant and anti-inflammatory properties may represent new alternatives in preventing cellular lesions in retinal ischemia. In this study, we report the neuroprotective effects of CGA and 4,5-di-O-[E]-caffeoylquinic (CQA) acid, isolated from Lychnophora plants, in a rodent glaucoma model. Wistar rats were administered intravitreally with 10 µg CGA or CGA, and then subjected to acute retinal ischemia (ISC) by increasing intraocular pressure (IPO) for 45 minutes followed (or not) by 15 minutes of reperfusion (I/R). Qualitative and quantitative analyses of neurodegeneration were performed using hematoxylin-eosin or Fluoro-Jade C staining protocols. All retinas submitted to ISC or I/R exhibited matrix disorganization, pyknotic nuclei, and pronounced vacuolization of the cytoplasm in the ganglion cell layer (GCL) and inner nuclear layer (INL). Pretreatment with CGA or CQA resulted in the protection of the retinal layers against matrix disorganization and a reduction in the number of vacuolized cells and pyknotic nuclei. Also, pretreatment with CGA or CQA resulted in a significant reduction in neuronal death in the GCL, the INL, and the outer nuclear layer (ONL) after ischemic insult. Our study demonstrated that CGA and CQA exhibit neuroprotective activities in retinas subjected to ISC and I/R induced by IPO in Wistar rats.

Key words

Lychnophora ericoides, compositae - Asteraceae - 4,5-di-O-[E]-caffeoylquinic acid - chlorogenic acid - acute rat retinal ischemia - neuroprotection

Abbreviations

ANOVA: analysis of variance

AP-1: Activating protein-1

Bax: Bcl-2-associated X-protein

BCG: Mycobacterium bovis Calmette-Guérin Bacillus

BDNF: brain-derived neurotrophic factor

CAPE: caffeic acid phenethyl ester

CAT: catalase

CGA: chlorogenic acid

CQA: 4,5-di-O-[E]-caffeoylquinic acid

EMR: electromagnetic radiation

FJC: Fluoro-Jade C

GCL: Ganglion cell layer

GSH-Px: phospholipid hydroperoxide glutathione peroxidase

INL: inner nuclear layer

IOP: intraocular pressure

LCA: licarin A

MAPK: mitogen-activated protein kinase

MDA: malondialdehyde

n-BuOH: n-butanol

NF-κB: nuclear factor kappa-light-chain-enhancer of activated B cells

NO: nitric oxide

Nrf2: Nuclear factor-erythroid 2 related factor 2

ONL: outer nuclear layer

PGE2: Prostaglandin E2

PTEN: phosphatase and tensin homolog

RGC: retinal ganglion cell culture

RGC: retinal ganglion cells

ROS: reactive oxygen species

SEM: standard error of the mean

SOD: superoxide dismutase

TGF-β : transforming growth factor-beta

Thy-1: Thy-1 cell surface antigen

TNF-α : tumor necrosis factor alpha

VEGF: vascular endothelial growth factor
 

Introduction

Lychnophora ericoides Mart., identified in this study by Dr. João Semir from the Biology Institute of the State University of Campinas (UNICAMP, Campinas, SP, Brazil), is one of several species from Lychnophora (subtribe Lychnophorinae, Asteraceae), popularly known as “false arnica” or “Brazilian arnica”. Plants of the genus Lychnophora are used in traditional medicine as analgesic and anti-inflammatory agents [1]. Moreover, Gobbo-Neto et al. (2005) [2] also observed an anti-inflammatory activity from L. ericoides. The main compounds in the “arnicas” with significant biological activity are phenolic compounds, including chlorogenic acid (CGA) and its derivatives such as 4,5-di-O-caffeoylquinic acid (CQA), both compounds present at [Fig. 1] (a and b, respectively) [2], [3]. Compound CQA has been shown to have neuroprotective potential in an acute seizure model [4]. Furthermore, recently our group described an anti-inflammatory effect of another phenolic compound, licarin A (LCA), in a model of uveitis induced by Mycobacterium bovis Calmette-Guérin Bacillus (BCG). Intravitreal injection of LCA significantly reduced the levels of inflammatory cytokines tumor necrosis factor-alpha (TNF-α) and interleukin-6 [5]. These studies encouraged the investigation of these compounds from “Brazilian arnica” in ocular disease models.

Fig. 1 Chemical structures of chlorogenic acid (a) and its derivatives such as 4,5-di-O-caffeoylquinic acid (b).

In 2040, it is estimated that almost 111.8 million people worldwide will suffer from glaucoma, which causes irreversible blindness [6]. The primary cause of glaucoma is unknown, but several risk factors have been identified, including elevated intraocular pressure (IOP) and aging. Loss of vision in glaucoma is caused mainly by the death of retinal ganglion cells (RGC), the neurons that convey visual information from the retina to the brain. Lowering IOP is not enough to protect the retina neurons. Therefore, therapeutic strategies aimed at delaying or halting RGC loss, which would be valuable to save vision in glaucoma, are needed [7]. The ischemic zone, or penumbra, is an area where tissue does not immediately die, hence the surrounding neurons can still be protected from neurodegeneration, halting the injury process [8].

Some potential therapies, such as anti-inflammatory and antioxidant drugs [9], [10], both developed from synthetic [11] and natural compounds [4] have been studied in glaucoma experimental models. In this regard, natural compounds with antioxidant and anti-inflammatory properties may represent an attractive approach to preventing neuronal death progression in the area surrounding the ischemic zone deeply related to inflammatory process. In vitro and in vivo studies demonstrated that CGA, which is the major component of coffee, reduces apoptosis of retinal cells induced by hypoxia and nitric oxide (NO) and that coffee consumption may help prevent retinal degeneration [12]. Previous studies suggested that CGA and its derivates have significant anti-inflammatory effects [2], [3]. Additionally, CGA derivatives had significant effects on reducing prostaglandin-E2 (PGE₂) and (TNF-α) production [13], factors closely related to excitotoxicity in glaucoma [14].

Collectively, these studies encouraged us to investigate the potential properties of CQA and CGA extracted from the “Brazilian arnica” in a glaucoma experimental model of acute retinal ischemic injury in Wistar rats.

Results

A comparison of previous isolated standards and the high performance liquid chromatography tandem mass spectrometry (LC-MS/MS) analysis [15] confirmed the identification of the major isolated secondary metabolites as CQA (not shown).

[Fig. 2] shows micrographs of the retinas in the following groups: Sham contralateral retinas (SHAM), ischemic retinas (ISC); chlorogenic acid-treated ischemic retinas (CGA+ISC); 4,5-di-O-[E]-caffeoylquinic acid-treated ischemic (CQA+ISC). As illustrated, the ganglion cell layer (GCL) and inner nuclear layer (INL) from retina submitted to ISC contained pyknotic nuclei (head arrows) and cytoplasm vacuolization (arrows). All retinas of the acute retinal ischemia-reperfusion (I/R) group exhibited matrix disorganization, vacuolization, pyknotic nuclei, and pronounced vacuolization of the cytoplasm in GCL and INL compared to the sham-control retinas ([Fig. 3]). Retinas treated with CGA or CQA acids were qualitatively protected against histological lesion features in different levels ([Fig. 3]). These histological alterations were not observed in the contralateral eyes (SHAM group).

Fig. 2 Neuroprotective effects of chlorogenic acid (CGA) and 4,5-di-O-[E]-caffeoylquinic acid (CQA) treatments on acute retinal ischemia (ISC). Representative photomicrographies of transverse sections of rat retinas stained with hematoxylin-eosin: Sham contralateral retinas (SHAM), ischemic retinas (ISC); chlorogenic acid-treated ischemic retinas (CGA+ISC); 4,5-di-O-[E]-caffeoylquinic acid-treated ischemic (CQA+ISC). Arrows point to vacuolization and head arrows to pyknotic nuclei. Scale bar = 50 µm (5 × magnification).

Fig. 3 Neuroprotective effects of chlorogenic acid (CGA) and 4,5-di-O-[E]-caffeoylquinic acid (CQA) treatment on acute retinal ischemia-reperfusion (I/R). Representative photomicrographies of transverse sections of rat retinas stained with hematoxylin-eosin: Sham contralateral retinas (SHAM), ischemic-reperfused retinas (I/R); chlorogenic acid-treated ischemic-reperfused retinas (CGA+I/R); 4,5-di-O-[E]-caffeoylquinic acid-treated ischemic-reperfused retinas (CQA+I/R). Arrows point to vacuolization, and head arrows point to pyknotic nuclei Scale bar = 50 µm (5 × magnification).

The quantitative histological analysis of retinas showed a significant reduction of 41% in the average density of GCL neurons in the ISC group compared to the SHAM group (F_(3,16) = 13.6; p = 0.0001) ([Fig. 4 a]).

Fig. 4 Chlorogenic acid (CGA) and 4,5-di-O-[E]-caffeoylquinic acid (CQA) treatment on acute retinal ischemia (ISC). Histograms representing cell density (cells/mm²) (a) in the ganglion cell layer (GCL); (b) in the inner nuclear layer (INL); (c) cellular density in the outer nuclear layer (ONL). Data are expressed as mean ± SEM (n = 5). # p < 0.05; # # p < 0.001; # # # p < 0.0001 vs. SHAM group; * p < 0.05; *** p < 0.0001 vs. ISC group.

Pretreatment with CGA, although it slightly reduced retinal ganglion cell culture (RGC) loss, had no significant protective effect ([Fig. 4 a]). Conversely, CQA effectively reduced the retinal damage in the CQA+ISC group (p = 0.0001). Compared to SHAMs, CQA treatment significantly decreased the RGC death to 20% (p = 0.0001).

As shown in [Fig. 4 b], the density of RGC also was decreased in the INL of the ISC groups by 36% compared to the SHAM group (p = 0.0002). The pretreatment with CGA and CQA effectively reduced neuronal loss in the INL. There were significant differences in average density of cells among CGA+ISC and CQA+ISC (as compared to untreated ischemia (F_(3,16) = 12.3; p = 0.0002). We observed a reduction of 36% cell density in the INL of the ISC group, whereas, in the CGA+ISC and CQA+ISC groups, only 0.5% of neuronal loss was observed ([Fig. 4 b]).

The quantitative analyzes of average cell density of in the outer nuclear layer (ONL) showed a decrease of 16% in the ISC group compared to SHAM group (F_(3,16) = 6.8, p = 0.0037; [Fig. 4 c]). Pretreatment with CGA effectively protected the ONL from cell loss, as we observed a reduction of 3% in the average density of cells in the ISC group (p = 0.0037). The CQA+ISC group was not statistically different from the ISC group, although the pretreatment with CQA reduced the cell loss to 10% (p > 0.05) in comparison to the SHAM group ([Fig. 4 c]). All means ± SEM values for the experimental groups analyzed are shown in [Table 1].

Table 1 Cell density values for each layer of rat retina stained with hematoxylin-eosin on acute retinal ischemia (ISC) model.

RETINAL LAYERS	SHAM	ISC	CGA + ISC	ISC+CQA
Data are expressed as mean cell density (cells/mm2) ± SEM. One Way ANOVA followed by Student-Newman-Keuls (n = 5). # p < 0.05; ## p < 0.001; ### p < 0.0001 vs. SHAM group; * p < 0.05; *** p < 0.0001 vs. ISC group. Sham contralateral retinas (SHAM), ischemic retinas (ISC); chlorogenic acid-treated ischemic retinas (CGA+ISC); 4,5-di-O-[E]-caffeoylquinic acid-treated ischemic (CQA+ISC).
GCL	2,414 ± 63.2	1,424 ± 75.1###	1,630 ± 60.2###	1,953 ± 203.5#*
INL	10,056 ± 648.3	6,453 ± 395.2###	10,051 ± 377.8***	10,048 ± 579.1***
ONL	40,761 ± 1,153	34,098 ± 914.5##	39,494 ± 776.3*	336,747 ± 1,557

Next, we investigated the effect of CGA and CQA on the ischemia-reperfusion protocol. The data shown a cell loss of 60% in the GCL of the I/R group, when compared to SHAM group (F_(3,16) = 20.1; p = 0.0001) ([Fig. 5 a]).

Fig. 5 Chlorogenic acid (CGA) and 4,5-di-O-[E]-caffeoylquinic acid (CQA) treatment on acute retinal ischemia-reperfusion (I/R). Histograms representing cell density (cells/mm²) (a) in the ganglion cell layer (GCL); (b) in the inner nuclear layer (INL); (c) cellular density in the outer nuclear layer (ONL). Data are expressed as mean ± SEM (n = 5). ^{# #} p < 0.001; ^{# # #} p < 0.0001 vs. SHAM group; ^§ p < 0.05; ^§§ p < 0.001 vs. I/R group.

Pretreatment with CGA had no significant protective effect on I/R model. Conversely, CQA administration effectively reduced the RGC loss to 35% in the CQA+I/R group when contrasted to I/R group (p = 0.0001) ([Fig. 5 a]).

A reduction of 48% in the INL cell density was observed in the I/R group in comparison to the SHAM group. Pretreatment with CGA and CQA effectively protected the INL against the neuronal loss in the retinal ischemia-reperfusion protocol in 15% and 10%, respectively (F_(3,16) = 8.6; p = 0.0012) ([Fig. 5 b]).

The I/R group resulted in a decrease of 25% in the neuronal density in the ONL compared to the SHAM group (F_(3,16) = 6.791, p = 0.0037; [Fig. 5 c]). Pretreatment with CGA and CQA reduced the cellular loss in the retinal ischemia-reperfusion model to 11% and 4%, respectively, in comparison to the I/R group (p = 0.0019) ([Fig. 5 c]).

All means ± SEM values for the experimental groups analyzed are shown in [Table 2].

Table 2 Cell density values for each layer of Wistar rat retina stained with hematoxylin-eosin on acute ischemia-reperfusion (I/R) model.

RETINAL LAYERS	SHAM	I/R	ICGA+I/R	ICQA+I/R
Data are expressed as mean cell density (cells/mm2) ± SEM. ANOVA one way followed by Student-Newman-Keuls. (n = 5). ## p < 0.001; ### p < 0.0001 vs. SHAM group; § p < 0.05; §§ p < 0.001 vs. I/R group. Sham contralateral retinas (SHAM), ischemic retinas (I/R); chlorogenic acid-treated ischemic retinas (CGA+I/R); 4,5-di-O-[E]-caffeoylquinic acid-treated ischemic (CQA+I/R).
GCL	2,451 ± 45.3	942.8 ± 97.8###	1,486 ± 191.7###*	1,504 ± 172.2###*
INL	10,110 ± 618.8	5,230 ± 371.9##	8,598 ± 981.9**	9,093 ± 766.3**
ONL	41,794 ± 1,511	30,464 ± 2,105##	36,108 ± 1,349§	39,197 ± 1,893§§

FJC staining was used to evaluate neuronal degeneration after retinal ischemia and retinal ischemia-reperfusion protocols to validate the H-E staining analysis. In this study we prioritized analysis of the RGC in the GCL, as it is the most susceptible to death by ischemic injury, although the degenerative process can be found in the other layers of the retina ([Fig. 6 a] and [7 a]).

Fig. 6 Effects of chlorogenic acid (CGA) and 4,5-di-O-[E]-caffeoylquinic acid (CQA) treatments against ganglion cells layer (GCL) neurodegeneration on acute retinal ischemia (ISC) model. a representative photomicrographies of transverse sections of rat retinas stained with Fluoro-Jade C (FJC). Sham contralateral retinas (SHAM), ischemic retinas (ISC); CGA-treated ischemic retinas (CGA+ISC); CQA-treated ischemic (CQA+ISC). White arrows point to FJC-positive neurons. No FJC-positive neurons were detected in the SHAM group. Scale bar: 50 µm (5 × magnification). b The histogram represents FJC-positive neurons in the ganglion cell layer (GCL) from the Wistar rat retina. Data are expressed as mean ± SEM (n = 5). ^### p < 0.0001 vs. SHAM group; *** p < 0.0001 vs. ISC group; ^% p < 0.05 vs. CQA+ISC group.

Fig. 7 Effects of chlorogenic acid (CGA) and 4,5-di-O-[E]-caffeoylquinic acid (CQA) treatment against ganglion cells layer (GCL) neurodegeneration on acute retinal ischemia-reperfusion (I/R) model. a representative photomicrographies of transverse sections of rat retinas stained with Fluoro-Jade C (FJC). Sham contralateral retinas (SHAM), ischemic retinas (ISC); chlorogenic acid-treated ischemic retinas (CGA+I/R); 4,5-di-O-[E]-caffeoylquinic acid-treated ischemic (CQA+I/R). White arrows point to FJC-positive neurons. No FJC-positive neurons were detected in the SHAM group. Scale bar: 50 µm (5 × magnification). b The histogram represents FJC-positive neurons in the ganglion cell layer (GCL) from the Wistar rat retina. Data are expressed as mean ± SEM (n = 5). ^### p < 0.0001 vs. SHAM group; ^§§§ p < 0.0001 vs. I/R group.

The average of FJC-positive neurons in the GCL was 6.4 in the ISC group (6.4 ± 0.2). Retinas pretreated with CGA and CQA exhibited a significant reduction on the average of FJC-positive neurons in the CGA+ISC and CQA+ISC groups (F_(3,16) = 74.5; p < 0.0001), as illustrated in [Fig. 6 b].

The number of neurodegenerating neurons in the I/R group is 6.2 ± 0.4 (p < 0.0001) in comparison to 0.0 ± 0.0 in the SHAM group ([Fig. 7 b]).

Pretreatments with CGA and CQA resulted in a significant reduction in the number of FJC-positive neurons in the I/R group, with an average of 3.4 neurons in the CGA+I/R group and 4.7 in the CQA+I/R group in comparison to I/R group (F_(3,16) = 55.97, p < 0.0001) ([Fig. 7 b]).

Discussion

Treatments for acute and chronic neurological diseases like Alzheimerʼs, Parkinsonʼs, epilepsy, stroke, and retinal neuropathologies such as glaucoma have had limited success and often exhibit undesired side effects. Consequently, there is a pressing unmet need for effective treatments for these diseases. In this context, pharmacological studies of natural products with the goal of developing new drugs are crucial. Natural products are an abundant source of new bioactive molecules that can be helpful to identity new compounds with neuroprotective activity. In this context, Brazil stands out as a rich source of biodiversity globally, which can provide an arsenal of potential neuroactive compounds from both animals and plants [16].

Acute experimental glaucoma, a model of ischemic insult, simulates the enhancing of IOP for a limited period and it has been employed in many studies [17]. There are many advantages of this model, such as being a relatively simple procedure, allowing for good control over the ischemic injury area, and for studying details of the I/R period [17], [18], [19].

Ischemia and I/R injury trigger deadly pathways induced by glutamate-excitotoxicity, free radical-mediated injury, and inflammatory mechanisms [20]. Consequently, a potential effective neuroprotective molecule should derail some of these cascade pathways [21]. In this work we investigated natural compounds like CGA and CQA, as they have previously shown to have anti-inflammatory, antioxidant, and neuroprotective effects. CGA is an ester of caffeic acid and quinic acid [22], and are known to have anti-inflammatory [23], and antioxidant [24]. Hence, further investigation of CGA and CQA may be helpful in the search for novel therapies. To the best of our knowledge, this is the first report evaluating CGA and CQA in models of acute retinal ischemia and – acute retinal I/R induced by increased intraocular pressure in Wistar rats.

Our data demonstrated that acute retinal ischemia and I/R induced significant cellular disorganization of the GCL, INL, and ONL. Additionally, we observed an increase of pyknotic nuclei and pronounced vacuolization of the cellular cytoplasm in all retinal layers. Such results are similar to data previously reported by others [18], [19]. In addition, the neuronal density was greatly reduced in the GCL (40% in ISC and 60% in I/R groups), INL (36% in ISC and 45% in I/R groups), and ONL (16% in ISC and 25% in I/R groups), with the group that went through reperfusion (I/R group) showing more damage than the ischemic retinas group (ISC). It is expected that I/R results in more damage than ischemia [25].

Intravitreal pre-treatments with CGA or CQA resulted in significant preservation of the structural organization of retinal cells in GCL, INL, and ONL in both ISC and I/R groups. Our data demonstrated that CQA, but not CGA, protected the RGC against the injury after ischemia. However, CGA effectively protected the ONL layer from cell loss, whereas CQA did not have this effect. This result was unexpected, and further studies are needed to understand this effect thoroughly. Furthermore, both treatments were neuroprotective in the INL layer. This neuroprotective potential was also demonstrated with CGA and CQA in the ischemia-reperfusion protocol. The compounds significantly reduced neuronal loss in the CGL, INL, and ONL, even though the most severe retinal damage occurred after reperfusion. We suggest that this robust neuroprotective effect against an insult of greater magnitude is due, in addition to the intrinsic effects of CGA and CQA, to the prior initiation of treatment against damage caused by reperfusion. Thus, this pre-treatment would act in an early stage of the signaling cascade that culminates in cell death, minimizing the damage caused by ischemia and I/R.

Flavones and flavonols, the most important and common classes of natural products with anti-inflammatory and antioxidant activities [26], [27], share structural similarity with CGA and CQA, as they are phenols derivatives of caffeic acid. This led us to speculate they might act through similar mechanisms to offer neuroprotection. Some previous studies corroborate with this possibility; one study showed that these compounds have antioxidant properties by acting directly on reactive oxygen species (ROS), scavenging or metal ion chelation, since both terminate in redox homeostasis processes for cell survival along with the anti-inflammatory activity [28]. Other study reports that CQA had a higher antioxidant ability in comparison to other di-O-caffeoylquinic acids in hydroxyl radical (OH)-damaged bone marrow-derived mesenchymal stem cells, which could be due to electron transfer, H⁺-transfer, and Fe²⁺-chelating due to relative positions of two caffeoyl moieties and to the conformational effect from the cyclohexane skeleton [29].

In vitro and in vivo studies demonstrated that CGA, which is a major component of coffee, significantly reduces apoptosis of retinal cells induced by hypoxia and nitric oxide (NO), and that coffee consumption may help prevent retinal degeneration [12], which is further supported by the fact that CGA crosses the Brain Blood Barrier [30]. Also, it has been reported that CGA prevents the downregulation of Thy-1 protein (Thy-1 cell surface antigen), an early marker of retinal ganglion cell culture (RGC) stress [12]. These previously reported mechanisms could be explored in the context of retinal glaucoma in future studies.

There are several examples of caffeic acid and its analogs with translational potential. For example, these compounds have been shown to offer tissue-protection against several models of ischemic lesion [31]. Caffeic acid phenethyl ester (CAPE) increased the activities of three antioxidant, including superoxide dismutase (SOD), catalase (CAT) and phospholipid hydroperoxide glutathione peroxidase (GSH-Px) in control rats in study of chronic exposition to electromagnetic radiation (EMR) emitted from a mobile phone for 60 days [32]. Retinal levels of NO and malondialdehyde (MDA), which are markers of lipid peroxidation, increase in EMR exposed rats, while CAPE significantly reduced their levels. CAPE significantly decreased MDA levels and increased the activities of SOD, GSH-Px, and CAT in a model of chronic retinal I/R injury induced by increasing the IOP for 60 min in rat retinas [33]. Additionally, CAPE attenuated the I/R-induced apoptosis of retinal cells in the INL and GCL, possibly by enhancing the antioxidation ability, which suggests that CAPE is potentially useful for treating I/R-induced eye disorders [33]. This data led us to speculate that, due to its similar chemical properties, the neuroprotective effects of CGA and CQA may involve an antioxidative activity that resulted in reduction of the ischemic cell death. Future studies will explore this possibility and the potential that CGA and CQA are more effective than the previously studied compounds.

Another study reported that pretreatment with CGA attenuated cell death in a concentration-dependent manner against retinal degeneration on optic nerve crush in a strain of albino mice from the Institute of Cancer Research in the USA (ICR) and in an in vitro retinal ganglion cell culture (RGC) hypoxic stress, possibly by preventing up-regulation of apoptotic proteins such as Bad and cleaved caspase-3 [34], which are potential mechanisms that could also be explored in the context of retinal glaucoma.

A plethora of antioxidants have been examined in models of chronic tissue injury; however, just a few studies have investigated the effects of CGA and CQA in a paradigm of acute ischemia model. In this context, we suggest that pretreatment with CQA and CGA promotes an intravitreal environment that somehow attenuates the cascade of deleterious events triggered by retinal ischemia. Shin et al. reported that both CQA and CGA could act, for example, in the interaction with vascular endothelial growth factor (VEGF) [35]. Inhibition of nuclear factor kappa B (NF-κB) and activating protein-1 (AP-1) may also be targets of action by CGA and CQA, as suggested by Feng et al. They reported for the first time that the effects of CGA may be through its up-regulation of cellular antioxidant enzymes and suppression of ROS-mediated NF-κB, AP-1, and mitogen-activated protein kinase (MAPK) activation [36]. All of these targets are directly or indirectly related to signaling pathways that could increase cell survival.

A recent study shows that CGA prevents oxidative stress and inflammation in liver stellate cells and fibroblast cells during liver fibrosis by inhibiting TGF-β (transforming growth factor-beta) and Nrf2 (Nuclear factor-erythroid 2 related factor 2) signaling pathways [37]. Additionally, Chen et al. reported that CGA administration alleviated spinal cord injury via anti-inflammatory activity mediated by nuclear factor NF-κB and MAPK [38]. A study of the effects of CGA in treating inflammation and alleviating the severity of colitis showed that CGA acts by suppressing phosphorylated extracellular signal-regulated kinases 1 and 2 (ERK1/2), c-Jun N-terminal kinases 1 and 2 (JNK1/2), Akt, and signal transducer and transcription activator 3 (STAT3) with concomitant upregulation of phosphatase and tensin homolog (PTEN) expression. Therefore, CGA and CQA are noticeable potential therapeutic agents since new molecules targeting TGF-β (transforming growth factor-beta), MAPK, BDNF (brain-derived neurotrophic factor), or PTEN (phosphatase and tensin homolog) have shown preliminary success in animal models and even human trials, demonstrating that they may eventually be used to preserve retinal neurons and vision [39].

In addition, CGA showed a dose-dependent decrease in p65 subunit expression of NF-κB and suppression of tumor necrosis factor-alpha (TNF-α) expression of pro-inflammatory cytokines. Also, the attenuation of apoptosis and oxidative stress induction was dose-dependent by suppressing the expression of Bcl-2-associated X-protein (Bax), caspase-8, caspase-9, and heme oxygenase-1 (HO-1) proteins in mice administered with CGA. These studies confirm the potential of CGA to suppress the activation of pro-inflammatory and apoptotic signaling pathways [40].

Additionally, the neurotransmitter glutamate plays an important role in the neurodegenerative cascade, predominantly through the N-methyl-D-aspartate (NMDA) subtype of glutamate receptor. CGA was shown to be neuroprotective by preventing calcium influx in a model of glutamate-induced neuronal death in mouse primary cortical cultures [41]. A recent study demonstrated that CGA inhibited 4-aminopyridine (4-AP)-induced glutamate release from cortical synaptosomes by suppressing the activation of P/Q-type calcium channels and CaMKII/synapsin I pathways [42] Additionally, CGA reduced glutamate release from microglia and significantly decreased cell death induced by hydrogen peroxide in primary neuron cultures [43]. Future studies will explore whether the mechanism of neuroprotection of CGA and CQA in our retinal model involves modulation of NMDA receptors and calcium channels.

Our results highlight the potential of these compounds to preserve retinal structure and cells against degeneration caused by increased IOP in models of ischemia and reperfusion. Limitations of this study include lack of clarity of the mechanisms involving CGA and QCA neuroprotective effects. Further studies will aim at identifying possible mechanisms of action, evaluating apoptotic, oxidative stress, and inflammatory signaling pathways in the model of ischemia and ischemia-reperfusion induced by IOP increase.

This study shows that chlorogenic and 4,5-di-O-[E]-caffeoylquinic acids exhibit neuroprotective activity in models of acute retinal ischemia and – acute retinal ischemia-reperfusion induced by increased intraocular pressure in Wistar rats. Pretreatments with these compounds preserved the structure of the retinal ganglionic layers and reduced neuronal death in the GCL, INL, and ONL.

Material and Methods

Plants and extracts

Leaves of Lychnophora ericoides were collected in Ibiraci, MG, Brazil by Dr. Norberto Peporine Lopes, and a voucher specimen was deposited at the Biology Institute of the State University of Campinas (UNICAMP), Campinas, SP, Brazil (NPL-123; herbarium UEC). L. ericoides polar extracts (Asteraceae, Asterales) were obtained from the Plant Extract Processing Laboratory bank from the Laboratory of Organic Chemistry, Physics and Chemistry Department, School of Pharmaceutical Sciences of Ribeirão Preto/University of São Paulo. A methanolic extract of L. ericoides was prepared from shade-dried leaves, that potentially increases the probability of finding chlorogenic acid derivatives [44], which was the goal of this study. In summary, initially the leaves were slowly dried in the shade for 10 days. The leaves were then air-dried, powdered (200 g) and extracted with 2.5 L of MeOH for 24 h at room temperature providing 15 g of the methanolic extract. The hydroalcoholic extract was partitioned between n-butanol (n-BuOH; Merck) and water. The n-BuOH-acetic acid phase was concentrated by rota-evaporation (60 °C) and the aqueous phase was concentrated by lyophilization.

Isolation of 4, 5-di-O-[E]-caffeoylquinic acid (CQA)

The extract was fractionated as previously described by Santos et al. (2005) [3] and Taleb-Contini et al. (2008) [4]. Briefly, aliquots of the polar fractions of extracts were fractionated on a column Sephadex LH-20 (Sigma-Aldrich) using methanol (Sigma-Aldrich) as eluent. The fractions resulting from this process were monitored in thin layer chromatography on silica plates using n-BuOH acetic acid and water (60 : 15 : 25, v/v) as solvent system. The process was monitored with ultraviolet light (254 and 366 nm).

Chemicals

Chlorogenic acid (CGA) was purchased from Sigma-Aldrich.

Animals and ethical statement

Adult male Wistar rats (280 – 320 g) were obtained from the Central Vivarium of the University of São Paulo, Ribeirão Preto Campus, and housed in the animal facility at the Department of Biology (FFCLRP-USP). The rats were housed in groups of 3 per cage with food and water available ad libitum. The animals were maintained in a controlled environment with 23 ± 2 °C, 60 ± 5% humidity, and a light-dark cycle of 12 h.

All experiments were performed following the guidelines for animal care from the Committee on Care and Use of Laboratory Animal Resources, from National Research Council (USA), which regulates the procedures for the scientific use of animals, and the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research. Ethics Committee for Care and Use of Laboratory Animals from Ribeirão Preto University of São Paulo Campus (CEUA) approved this work at December 07th, 2010, under the protocol number CEUA 2010.1.795.53.6.

Acute retinal ischemia or ischemia-reperfusion injury

Acute retinal ischemia or I/R models were induced in rats according to Louzada-Júnior et al. (1992) [19] and Guizzo et al. (2005) [18]. Briefly, animals were anesthetized with urethane (2.5 g/kg, via intraperitoneal; Acros Organics), and a sterile 27-gauge needle, attached to a manometer/pump, was inserted into the anterior chamber of the left eye to increase the IOP to 120 mm/Hg above systemic systolic blood pressure for 45 min to induce retinal ischemia. The appearance of a pale fundus confirmed the blood flow interruption.

After 45 min, the IOP was reduced to normal levels for 15 min. This is the reperfusion period when the eye fundus color returned to rose.

The contralateral retinas served as sham-controls (SHAM), and for this reason, the cannula was inserted into the anterior chamber of the right eye, but the IOP was not increased. The rats were kept over a heating pad to ensure that the body temperature was maintained above 37 °C during all experimental procedures.

The rats were administered with 1 µL of vehicle (dH₂O), CGA (10 µg/µL; diluted in dH₂O) or CQA (10 µg/µL; diluted in dH₂O), via intravitreal 15 min before the insults. These doses were determined by a prior trial (data not shown) based on the study of Santos et al. (2010) [13], which reported that caffeoylquinic acid derivatives produced inflammatory mediators in cultured cells [13]. Additionally, these compounds were shown to cross the blood-brain barrier [30].

Five rats were used in each group: retinal ischemia group (ISC) treated with vehicle, CGA or CQA (CGA+ISC and CQA+ISQ), and retinal ischemia-reperfusion group (I/R) treated with vehicle, CGA and CQA (CGA+I/R and CQA+I/R). As described above, ipsilateral retinas received the indicated insults, whereas contralateral retinas did not receive insults (SHAM).

Additionally, tree rats per group were administered vehicle, CGA or CQA, without any insult. When compared to the SHAM group, no morphological differences were found between retinas administered with CGA, CQA, or vehicle (not shown), so only five SHAM retinas, randomly chosen, were analyzed in this study. A total of 39 rats were used in this work. [Fig. 8] depicts the protocols used in this study.

Fig. 8 Schematic representation of the experimental protocols used. a experimental protocol for induction of retinal ischemia (ISC) and b experimental protocol for retinal ischemia-reperfusion (I/R). c The contralateral retinas served as a sham-control (SHAM), so the cannula was inserted into the anterior chamber of the right eye, but the IOP was not increased. The figures were created in BioRender.com.

Histology

Hematoxylin-eosin (H-E)

Animals were euthanatized immediately after retinal ischemia or I/R protocols by an overdose of urethane (3 g/kg; Sigma-Aldrich), and the eyes were rapidly enucleated and fixed in Bouinʼs solution (75% picric acid, 25% formalin, and 5% acetic acid) for 24 hours. Once fixed, the corneas and lenses were removed, leaving a chalice-shaped structure for the eyecups used for diaphanization and dehydration. The eyecups (structure C shape) were included in paraffin in a standardized position using the muscle tissue located in the supranasal part as reference. After embedding in paraffin, retinas were sectioned in a sagittal plane at 5 µm, stained with H-E, and examined using a light/fluorescent microscope (Leica DM5000B).

Microscopic images (1392 × 1040 pixels) were captured from three retina sections of each eye using the bright field of an epifluorescence microscope (Leica DM5000B) linked to a digital camera (Leica DFC300FX) connected to a computer. The cellular quantification (15 measurements per group) was based upon the number of non-pyknotic nuclei in the nuclear layers of the retina. The condensation of chromatin characterizes pyknotic nuclei. This counting was performed by ImageJ (National Institutes of Health; version 1.53 k) using a blind fashion counting. The areas of the layers were measured by Q-Win software (Leica) in a blind manner. The results were normalized using the Abercrombie correction method, according to the following formula:

N (per mm²) = n [T/(T+D)]/A

Where N is the real number of cells, n is the number of cells observed; T is the section thickness, D is the diameter of the nuclei in each region, and A is the measured area (mm²). Results were expressed as mean cell density ± standard error of the mean (SEM).

Fluoro-Jade C staining)

Fluoro-Jade C (FJC; Sigma-Aldrich) staining is widely used for the specific detection of degenerating neurons. We used a protocol according to Schmued et al. (2005) [45], with modifications.

Briefly, 6 µm-thick retinal sections were stretched on previously gelatinized slides and kept in an oven at 37 °C for 24 hours. The sections were deparaffinized by three washes of xylene, rehydrated in two washes of absolute ethanol, one of 95%, one of 75%, and one in distilled water. Sections were transferred to 0.06% potassium permanganate for 13 min, washed in distilled water, and incubated in 0.0001% FJC. Slides were washed in distilled water three times for 1 min and mounted with 1 : 1 (v/v) solution of Fluoromount (Sigma-Aldrich) and 0.1% acetic acid. The sections were examined using a light source of a high-pressure mercury lamp and an excitation filter to fluorescein/FITC. Five ganglion cell layer (GCL) microscope fields with the same standard area of the region of interest (1392 × 1040 pixels) were analyzed per group. Results were expressed as mean cells FJC-positive per image photographed ± standard error of the mean (SEM).

Statistical analysis

The treatment effects among the groups were compared using a one-way analysis of variance (ANOVA) followed by the Newman-Keuls post-hoc test. p-values below 0.05 were considered statistically significant. Data was analyzed with Graph Prism (version 8.0, GraphPad Software).

Contributorsʼ Statement

J. L.L wrote, reviewed, and edited the manuscript, also contributed to data analysis tools; M. N. R. performed the experiments, collected, and analyzed the data; M. C. R. M. performed the experiments and collected the data; J. L. C. L. conceived and designed the analysis, wrote the manuscript; L. G. N. isolated the CQA compound, collected the data, performed the analysis; A. C. K. F. conceived and designed the analysis, wrote, reviewed and edited the manuscript; N. P. L. conceived and designed the analysis, wrote the paper and acquired funding; W. F. S. conceived and designed the analysis, wrote, reviewed, and edited the manuscript, and acquired funding.

Conflict of Interest

The authors declare that they have no conflict of interest.

Acknowledgements

This research was supported by São Paulo State Research Foundation (FAPESP, Brazil) grant numbers [2005/60254-0] and [2008/09389-0]; JLL was a recipient of a research scholarship from the National Council for Scientific and Technological Development (CNPq, Brazil); JLL and MNR were also recipients of research scholarships from the Coordination for the Improvement of Higher Education Personnel (CAPES, Brazil).

• References

• 1 Keles LC, de Melo NI, Aguiar PG, Wakabayashi KAL, de Carvalho CE, Cunha WR, Crotti EAM, Luis J, Callegari Lopes JL, Lopes NP. Lychnophorinae (Asteraceae): A survey of its chemical constituents and biological activities. Quim Nova 2010; 33: 2245-2260 DOI: 10.1590/S0100-40422010001000038.
• 2 Gobbo-Neto L, Santos MD, Kanashiro A, Almeida MC, Lucisano-Valim YM, Lopes JL, Souza GE, Lopes NP. Evaluation of the anti-inflammatory and antioxidant activities of di-C-glucoflavones from Lychnophora ericoides (Asteraceae). Planta Med 2005; 71: 3-6 DOI: 10.1055/s-2005-837742.
• 3 dos Santos MD, Gobbo-Neto L, Albarella L, de Souza GE, Lopes NP. Analgesic activity of di-caffeoylquinic acids from roots of Lychnophora ericoides (Arnica da serra). J Ethnopharmacol 2005; 96: 545-549 DOI: 10.1016/j.jep.2004.09.043.
• 4 Taleb-Contini SH, Santos WF, Mortari MR, Lopes NP, Lopes JL. Neuropharmacological effects in mice of Lychnophora species (Vernonieae, Asteraceae) and anticonvulsant activity of 4, 5-di-O-[E]-caffeoylquinic acid isolated from the stem of L. rupestris and L. staavioides. Basic Clin Pharmacol Toxicol 2008; 102: 281-286 DOI: 10.1111/j.1742-7843.2007.00194.x.
• 5 Paiva MRB, Vasconcelos-Santos DV, Coelho MM, Machado RR, Lopes NP, Silva-Cunha A, Fialho SL. Licarin A as a novel drug for inflammatory eye diseases. J Ocul Pharmacol Ther 2021; 37: 290-300 DOI: 10.1089/jop.2020.0129.
• 6 Tham YC, Li X, Wong TY, Quigley HA, Aung T, Cheng CY. Global prevalence of glaucoma and projections of glaucoma burden through 2040. Ophthalmology 2014; 121: 2081-2090 DOI: 10.1016/j.ophtha.2014.05.013.
• 7 Cheung W, Guo L, Cordeiro MF. Neuroprotection in glaucoma: Drug-based approaches. Optom Vis Sci 2008; 85: 406-416 DOI: 10.1097/OPX.0b013e31817841e5.
• 8 Ermine CM, Bivard A, Parsons MW, Baron JC. The ischemic penumbra: From concept to reality. Int J Stroke 2021; 16: 497-509 DOI: 10.1177/1747493020975229.
• 9 Ige M, Liu J. Herbal Medicines in Glaucoma Treatment. Yale J Biol Med 2020; 93: 347-353
• 10 Pinazo-Duran MD, Shoaie-Nia K, Zanon-Moreno V, Sanz-Gonzalez SM, Del Castillo JB, Garcia-Medina JJ. Strategies to reduce oxidative stress in glaucoma patients. Curr Neuropharmacol 2018; 16: 903-918 DOI: 10.2174/1570159X15666170705101910.
• 11 Kobayashi H. Efficacy of single glaucoma drug in combined timolol XE, latanoprost and brinzolamide therapy: a discontinuation study. J Ocul Pharmacol Ther 2012; 28: 245-250 DOI: 10.1089/jop.2011.0128.
• 12 Jang H, Ahn HR, Jo H, Kim KA, Lee EH, Lee KW, Jung SH, Lee CY. Chlorogenic acid and coffee prevent hypoxia-induced retinal degeneration. J Agric Food Chem 2014; 62: 182-191 DOI: 10.1021/jf404285v.
• 13 dos Santos MD, Chen G, Almeida MC, Soares DM, de Souza GE, Lopes NP, Lantz RC. Effects of caffeoylquinic acid derivatives and C-flavonoid from Lychnophora ericoides on in vitro inflammatory mediator production. Nat Prod Commun 2010; 5: 733-740
• 14 Christensen I, Lu B, Yang N, Huang K, Wang P, Tian N. The susceptibility of retinal ganglion cells to glutamatergic excitotoxicity is type-specific. Front Neurosci 2019; 13: 219 DOI: 10.3389/fnins.2019.00219.
• 15 Gobbo-Neto L, Lopes NP. Online identification of chlorogenic acids, sesquiterpene lactones, and flavonoids in the Brazilian arnica Lychnophora ericoides Mart. (Asteraceae) leaves by HPLC-DAD-MS and HPLC-DAD-MS/MS and a validated HPLC-DAD method for their simultaneous analysis. J Agric Food Chem 2008; 56: 1193-1204 DOI: 10.1021/jf072812l.
• 16 Mortari MR, Cunha AO, Ferreira LB, dos Santos WF. Neurotoxins from invertebrates as anticonvulsants: From basic research to therapeutic application. Pharmacol Ther 2007; 114: 171-183 DOI: 10.1016/j.pharmthera.2007.01.009.
• 17 Osborne NN. Recent clinical findings with memantine should not mean that the idea of neuroprotection in glaucoma is abandoned. Acta Ophthalmol 2009; 87: 450-454 DOI: 10.1111/j.1755-3768.2008.01459.x.
• 18 Guizzo R, Rodrigues MCA, Coutinho-Netto J, Silva ARM, Coimbra NC, Santos WF. Neuroprotection in acute ischemia and ischemia/reperfusion in rat retina. Int J Pharmacol 2005; 1: 369-375 DOI: 10.3923/ijp.2005.369.375.
• 19 Louzada-Júnior P, Dias JJ, Santos WF, Lachat JJ, Bradford HF, Coutinho-Netto J. Glutamate release in experimental ischaemia of the retina: an approach using microdialysis. J Neurochem 1992; 59: 358-363
• 20 Belov Kirdajova D, Kriska J, Tureckova J, Anderova M. Ischemia-triggered glutamate excitotoxicity from the perspective of glial cells. Front Cell Neurosci 2020; 14: 51 DOI: 10.3389/fncel.2020.00051.
• 21 Fisher M. New approaches to neuroprotective drug development. Stroke 2011; 42: S24-S27 DOI: 10.1161/STROKEAHA.110.592394.
• 22 Mondolot L, La Fisca P, Buatois B, Talansier E, de Kochko A, Campa C. Evolution in caffeoylquinic acid content and histolocalization during Coffea canephora leaf development. Ann Bot 2006; 98: 33-40 DOI: 10.1093/aob/mcl080.
• 23 Abdel Motaal A, Ezzat SM, Tadros MG, El-Askary HI. In vivo anti-inflammatory activity of caffeoylquinic acid derivatives from Solidago virgaurea in rats. Pharm Biol 2016; 54: 2864-2870 DOI: 10.1080/13880209.2016.1190381.
• 24 Nakajima Y, Shimazawa M, Mishima S, Hara H. Water extract of propolis and its main constituents, caffeoylquinic acid derivatives, exert neuroprotective effects via antioxidant actions. Life Sci 2007; 80: 370-377 DOI: 10.1016/j.lfs.2006.09.017.
• 25 Wu MY, Yiang GT, Liao WT, Tsai AP, Cheng YL, Cheng PW, Li CY, Li CJ. Current mechanistic concepts in ischemia and reperfusion injury. Cell Physiol Biochem 2018; 46: 1650-1667 DOI: 10.1159/000489241.
• 26 Nabavi SF, Tejada S, Setzer WN, Gortzi O, Sureda A, Braidy N, Daglia M, Manayi A, Nabavi SM. Chlorogenic acid and mental diseases: From chemistry to medicine. Curr Neuropharmacol 2017; 15: 471-479 DOI: 10.2174/1570159X14666160325120625.
• 27 Dajas F, Andrés AC, Florencia A, Carolina E, Felicia RM. Neuroprotective actions of flavones and flavonols: Mechanisms and relationship to flavonoid structural features. Cent Nerv Syst Agents Med Chem 2013; 13: 30-35 DOI: 10.2174/1871524911313010005.
• 28 Hussain T, Tan B, Yin Y, Blachier F, Tossou MC, Rahu N. Oxidative stress and inflammation: What polyphenols can do for us?. Oxid Med Cell Longev 2016; 2016: 7432797 DOI: 10.1155/2016/7432797.
• 29 Li X, Li K, Xie H, Xie Y, Li Y, Zhao X, Jiang X, Chen D. Antioxidant and cytoprotective effects of the Di-O-Caffeoylquinic acid family: The mechanism, structure-activity relationship, and conformational effect. Molecules 2018; 23: 222 DOI: 10.3390/molecules23010222.
• 30 Kumar G, Paliwal P, Mukherjee S, Patnaik N, Krishnamurthy S, Patnaik R. Pharmacokinetics and brain penetration study of chlorogenic acid in rats. Xenobiotica 2019; 49: 339-345 DOI: 10.1080/00498254.2018.1445882.
• 31 Gurel A, Armutcu F, Hosnuter M, Unalacak M, Kargi E, Altinyazar C. Caffeic acid phenethyl ester improves oxidative organ damage in rat model of thermal trauma. Physiol Res 2004; 53: 675-682
• 32 Ozguner F, Bardak Y, Comlekci S. Protective effects of melatonin and caffeic acid phenethyl ester against retinal oxidative stress in long-term use of mobile phone: a comparative study. Mol Cell Biochem 2006; 282: 83-88 DOI: 10.1007/s11010-006-1267-0.
• 33 Shi Y, Wu X, Gong Y, Qiu Y, Zhang H, Huang Z, Su K. Protective effects of caffeic acid phenethyl ester on retinal ischemia/reperfusion injury in rats. Curr Eye Res 2010; 35: 930-937 DOI: 10.3109/02713683.2010.494820.
• 34 Jang H, Choi Y, Ahn HR, Jung SH, Lee CY. Effects of phenolic acid metabolites formed after chlorogenic acid consumption on retinal degeneration in vivo . Mol Nutr Food Res 2015; 59: 1918-1929 DOI: 10.1002/mnfr.201400897.
• 35 Shin JY, Sohn J, Park KH. Chlorogenic acid decreases retinal vascular hyperpermeability in diabetic rat model. J Korean Med Sci 2013; 28: 608-613 DOI: 10.3346/jkms.2013.28.4.608.
• 36 Feng R, Lu Y, Bowman LL, Qian Y, Castranova V, Ding M. Inhibition of activator protein-1, NF-kappaB, and MAPKs and induction of phase 2 detoxifying enzyme activity by chlorogenic acid. J Biol Chem 2005; 280: 27888-27895 DOI: 10.1074/jbc.M503347200.
• 37 Nwafor EO, Lu P, Zhang Y, Liu R, Peng H, Xing B, Liu Y, Li Z, Zhang K, Zhang Y, Liu Z. Chlorogenic acid: Potential source of natural drugs for the therapeutics of fibrosis and cancer. Transl Oncol 2022; 15: 101294 DOI: 10.1016/j.tranon.2021.101294.
• 38 Chen D, Pan D, Tang S, Tan Z, Zhang Y, Fu Y, Lü G, Huang Q. Administration of chlorogenic acid alleviates spinal cord injury via TLR4/NF-κB and p38 signaling pathway anti-inflammatory activity. Mol Med Rep 2018; 17: 1340-1346 DOI: 10.3892/mmr.2017.7987.
• 39 Gauthier AC, Liu J. Epigenetics and signaling pathways in glaucoma. Biomed Res Int 2017; 2017: 5712341 DOI: 10.1155/2017/5712341.
• 40 Vukelić I, Detel D, Pučar LB, Potočnjak I, Buljević S, Domitrović R. Chlorogenic acid ameliorates experimental colitis in mice by suppressing signaling pathways involved in inflammatory response and apoptosis. Food Chem Toxicol 2018; 121: 140-150 DOI: 10.1016/j.fct.2018.08.061.
• 41 Mikami Y, Yamazawa T. Chlorogenic acid, a polyphenol in coffee, protects neurons against glutamate neurotoxicity. Life Sci 2015; 139: 69-74 DOI: 10.1016/j.lfs.2015.08.005.
• 42 Hung YC, Kuo YH, Hsieh PW, Hsieh TY, Kuo JR, Wang SJ. Chlorogenic acid decreases glutamate release from rat cortical nerve terminals by P/Q-Type Ca²⁺ channel suppression: A possible neuroprotective mechanism. Int J Mol Sci 2021; 22: 11447 DOI: 10.3390/ijms222111447.
• 43 Socodato R, Portugal CC, Canedo T, Domith I, Oliveira NA, Paes-de-Carvalho R, Relvas JB, Cossenza M. c-Src deactivation by the polyphenol 3-O-caffeoylquinic acid abrogates reactive oxygen species-mediated glutamate release from microglia and neuronal excitotoxicity. Free Radic Biol Med 2015; 79: 45-55 DOI: 10.1016/j.freeradbiomed.2014.11.019.
• 44 Moreira EA, Pilon AC, Andrade LE, Lopes NP. New perspectives on chlorogenic acid accumulation in harvested leaf tissue: Impact on traditional medicine preparations. ACS Omega 2018; 3: 18380-18386 DOI: 10.1021/acsomega.8b02409.
• 45 Schmued LC, Stowers CC, Scallet AC, Xu L. Fluoro-Jade C results in ultra high resolution and contrast labeling of degenerating neurons. Brain Res 2005; 1035: 24-31 DOI: 10.1016/j.brainres.2004.11.054.

Publication History

Received: 28 March 2022

Accepted after revision: 27 June 2022

Article published online:
11 October 2022